Autolus Therapeutics (AUTL) announces that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended European Commission, EC, approval of obecabtagene autoleucel, obe-cel, for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. “This positive opinion from the CHMP highlights the significant unmet need and importance of effective treatment options for adult r/r B-ALL,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “With FDA approval received in November 2024 and an MHRA conditional marketing authorization received in April 2025, we are on our way to bringing this therapy to patients in need globally.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics presents clinical data updates at EHA Congress
- Autolus Therapeutics’ Earnings Call: AUCATZYL’s Strong Start Amid Financial Challenges
- Autolus Therapeutics Reports Q1 2025 Earnings and Progress
- Autolus Therapeutics files to sell 54.58M American depositary shares for holders
- Autolus Therapeutics: Strong Q1 Performance and Strategic Expansion Justify Buy Rating